(Q28728389)

English

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

scientific article (publication date: 2012)

In more languages

Statements

scholarly article

0 references

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension (English)

0 references

arterial hypertension

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

Per Eystein Lønning

8

object named as

Per E Lønning

0 references

7

object named as

Anders Molven

0 references

9

object named as

Lars A Akslen

0 references

Stephanie Geisler

5

object named as

Stephanie Geisler

0 references

Hans Petter Eikesdal

2

object named as

Hans P Eikesdal

0 references

Oddbjørn Straume

10

object named as

Oddbjørn Straume

0 references

Cornelia Schuster

1

object named as

Cornelia Schuster

0 references

Jürgen Geisler

4

object named as

Jürgen Geisler

0 references

author name string

Hanne Puntervoll

3

0 references

Daniel Heinrich

6

0 references

language of work or name

0 references

publication date

2012

0 references

0 references

7

0 references

6

0 references

e38364

0 references

copyright license

Creative Commons Attribution 4.0 International

15 June 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

17 March 2017

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

7 April 2017

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Targeting angiogenesis in melanoma: prospects for the future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Angiogenesis, lymphangiogenesis, and melanoma metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

Clinical applications of angiogenic growth factors and their inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

New designs for the selection of treatments to be tested in randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376108

20 June 2018

MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

Beta blockers and breast cancer mortality: a population- based study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0038364

21 January 2018

Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22719881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis is prognostically important in vertical growth phase melanomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/22719881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22719881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

https://pubmed.ncbi.nlm.nih.gov/22719881

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0038364

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2012PLoSO...738364S

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28728389&oldid=2120162100"